GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
03 août 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush...
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
29 juil. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on...
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
26 juil. 2022 03h01 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA)...
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
14 juil. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in...
GBT Inicia Programa de Acesso Expandido para Voxelotor em Pacientes com Doença Falciforme no Brasil
14 juil. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SÃO PAULO, July 14, 2022 (GLOBE NEWSWIRE) -- A Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) anunciou hoje o início do programa de acesso expandido (PAE) para o voxelotor no Brasil...
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
13 juil. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of...
GBT Announces New Employment Inducement Grants
07 juil. 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2022, the compensation committee of GBT’s board of...
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
29 juin 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial...
NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
16 juin 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced a new partnership with New York Jets running back Tevin Coleman and...
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
13 juin 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results from the Sickle Cell Health Awareness, Perspectives and...